Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Date:3/22/2011

EXTON, Pa., March 22, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced data presented in two poster presentations relating to Cinryze® (C1 esterase inhibitor [human]) at the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, March 18 through 22, in San Francisco, CA.  

Cinryze is the first and only U.S. FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease.  Cinryze is currently available only in the United States, and is not approved in the U.S. to treat acute angioedema attacks, for children with HAE, or for pre-procedure administration.

"As leaders in hereditary angioedema medical education, we continue to expand the body of data available on Cinryze usage," commented David Mariano, PharmD, ViroPharma's director of medical communications. "Our goal is to leverage educational initiatives to reinforce the understanding and awareness of HAE and its management for physicians and other healthcare professionals who may care for patients suffering from HAE."

AAAAI Poster Presentations

In a poster entitled, 'Pre-procedural Administration of Nanofiltered C1 Esterase Inhibitor (Human) (Cinryze®) for the Prevention of Hereditary Angioedema (HAE) Attacks after Medical, Dental, or Surgical Procedures,' Dr. William Lumry, M.D., of the University of Texas Southwestern Medical School in Dallas, Texas discussed the potential for Cinryze to prevent attacks of HAE that are triggered by trauma such as dental work, elective medical procedures and surgery.  Data compiled from all completed studies with Cinryze were presented on the experience of 41 subjects who received Cinryze prior to 91 procedures.  Cinryze 1000U
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
2. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
3. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
10. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
11. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... --  Metanome, Inc. , a Houston ... was the genomic sequencing provider for Seres Health,s ( ... of SER 109, an Ecobiotic® therapeutic for the treatment ... (CDI). Metanome has provided genomic sequencing services ... Such genomic characterization has enabled the study of the ...
(Date:10/25/2014)... 2014 Best Practices designed the Medical ... a forum for sharing insights about the key ... mechanism for creating and sharing solutions through three ... from the Medical Affairs Consortium survey. ... the first roundtable of the 2014-2015 Medical Affairs ...
(Date:10/22/2014)... 22, 2014  Rescheduling of hydrocodone combination products ... pain market, according to a new primary market ... providing market research and consultation exclusively in the ... http://photos.prnewswire.com/prnh/20141021/153440 In August, ... combination products from Schedule III to Schedule II ...
Breaking Medicine Technology:Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... COLLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstCall/ --,Wyeth ... Inc. and Lundbeck A/S presented clinical study,results ... this,week. Safety analyses suggest bifeprunox, an investigational,treatment ... with a favorable weight and lipid profile, ...
... is STD Awareness Month: Time to Pay Attention ... 2007 /PRNewswire/ -- During,National Sexually Transmitted Disease (STD) ... awareness of, and,testing for, trichomoniasis (also known as ... States. Awareness of the condition,remains low, despite the ...
Cached Medicine Technology:Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 2Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 3Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 4Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 5Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 6Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually 2Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million,Annually 3
(Date:10/25/2014)... October 25, 2014 TASC (Total ... and other benefits account management services, announces the ... employers save on taxes, reduce administrative workload, and ... tax savings and the efficient handling of complex, ... Suite that best meets their goals and objectives. ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Not getting the right amount ... a new study suggests. Those who sleep less ... per night may be more prone to developing the ... report. The study authors concluded that duration and quality ... patients with inflammatory bowel diseases. "Both short and ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
(Date:10/22/2014)... Isabel Healthcare will participate ... (ASAHP) Conference on October 22-24 in Las Vegas, NV. ... a panel discussion on Technology in Health Professions Education ... a diagnostic decision support tool and clinical education platform ... students and clinical learners. The Isabel tools help clinicians ...
Breaking Medicine News(10 mins):Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2
... for estrogen-sensitive tumor types, study found , , SUNDAY, April ... amounts, increases the risk of breast cancer and particularly ... shows. , The findings, expected to be presented Sunday ... Cancer Research, in San Diego, are followed by a ...
... Spectrometer is suitable for use in ... potentially explosive atmospheres, PITTSBURGH, April ... The MAX300-IGX Industrial Mass Spectrometer,is suitable for use in potentially ... obtained ATEX,approval for installations in Zone 1 areas. The MAX300-IGX ...
... the University of Pennsylvania School of Medicine and Abramson ... the American Association for Cancer Research that combining two ... lines. The team is currently designing a trial to ... is resistant to many chemotherapies and to cell-death inducing ...
... Calif., April 12 Over 300,healthcare workers at Coastal ... SEIU United Healthcare Workers - West (UHW) in a,secret-ballot ... "Uniting with thousands of other caregivers as a ... difference on the things that matter most," said,Ruth Calderon, ...
... YMCA Healthy Kids Day Saturday, April 12 ... Calif., April 11 The Mt. Diablo Region,YMCA will join ... Kids Day on Saturday, April 12 from 9 a.m. to ... Irvin Deutscher Family YMCA.,An opportunity for kids and families to ...
... researchers got paid but more upset when they owned ... volunteers in clinical studies aren,t overly concerned if researchers ... trust, suggests a U.S. study. , "Though peoples, willingness ... not suffer substantially based on the types of financial ...
Cached Medicine News:Health News:Drinking May Raise Breast Cancer Risk 2Health News:Extrel CMS Announces ATEX Approval for Process Mass Spectrometer 2Health News:Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer 2Health News:Coastal Communities Hospital Workers Join United Healthcare Workers 2Health News:The Mt. Diablo Region YMCA Invites Families to 'Put Play in Your Day' and Bring Healthy Habits Home During the Nation's Largest Health Day for Children and Families 2Health News:The Mt. Diablo Region YMCA Invites Families to 'Put Play in Your Day' and Bring Healthy Habits Home During the Nation's Largest Health Day for Children and Families 3Health News:Clinical Trial Volunteers Uneasy About Some Financial Ties 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: